Table 3.
Immunological assessment of the treatments
| CTL induction |
DTH induction (mmd) |
|||||
|---|---|---|---|---|---|---|
| Patient number | CD8+ tetramer+ lymphocytesa | Cytotoxicityb | IFN-γ releasec (pg/ml) | Baseline | Post-treatments | |
| Aex | A1 | ND | ND | ND | <2 | <2 |
| A2 | ND | ND | ND | <2 | ND | |
| A3 | ND | ND | ND | <2 | <2 | |
| A4 | ND | ND | ND | <2 | <2 | |
| A5 | 0.04 | ND | ND | <2 | <2 | |
| B1 | ND | ND | ND | <2 | <2 | |
| B2 | ND | ND | ND | <2 | <2 | |
| B3 | 0.02 | ND | ND | <2 | 4 | |
| B4 | ND | ND | ND | <2 | <2 | |
| B5 | ND | ND | ND | <2 | <2 | |
| C1 | 2.71 | 34.1 (10.3) | 1,109 (239) | 3 | 13 | |
| C2 | 0.03 | ND | ND | <2 | 6 | |
| C3 | 0.04 | ND | ND | <2 | 8 | |
| C4 | 0.02 | ND | ND | <2 | 6 | |
| C5 | ND | ND | ND | <2 | ND | |
| D1 | 0.03 | ND | ND | <2 | 3 | |
| D2 | 0.02 | ND | ND | 3 | 3 | |
| D3 | 1.53 | 29.3 (6.5) | 1,007 (225) | 3 | 9 | |
| D4 | 0.04 | ND | ND | <2 | 3 | |
| D5 | ND | ND | ND | <2 | 3 | |
| Aex + GM-CSF | E1 | ND | ND | ND | <2 | <2 |
| E2 | 2.01 | 31.9 (12.3) | 1,331 (227) | 3 | 12 | |
| E3 | ND | ND | ND | <2 | <2 | |
| E4 | ND | ND | ND | <2 | <2 | |
| E5 | ND | ND | ND | <2 | <2 | |
| F1 | 1.31 | 30.7 (8.4) | 1,100 (250) | 3 | 12 | |
| F2 | 0.04 | ND | ND | <2 | 3 | |
| F3 | ND | ND | ND | <2 | <2 | |
| F4 | 1.12 | 16.8 (4.3) | 776 (258) | <2 | 6 | |
| F5 | ND | ND | ND | <2 | <2 | |
| G1 | 4.85 | 50.2 (5.3) | 1,651 (253) | 6 | 18 | |
| G2 | 3.15 | 43.3 (7.7) | 1,522 (289) | 6 | 9 | |
| G3 | 2.75 | 34.7 (9.9) | 1,203 (241) | <2 | 16 | |
| G4 | 1.70 | 25.6 (4.2) | 985 (251) | <2 | 6 | |
| G5 | 0.03 | 2.2 (5.1) | ND | <2 | 5 | |
| H1 | ND | ND | ND | <2 | ND | |
| H2 | 0.92 | 17.8 (4.1) | 801(264) | <2 | 7 | |
| H3 | 1.45 | 28.7 (3.4) | 1,105 (233) | 4 | 14 | |
| H4 | 1.23 | 19.1 (6.8) | 907 (247) | <2 | 8 | |
| H5 | 0.01 | ND | ND | <2 | 3 | |
Abbreviations: Aex, ascites-derived exosomes; CTL, cytotoxic T lymphocytes; DTH, delayed-type hypersensitivity; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon γ; ND, not determined.
The results were presented as mean percentage of CD8+ tetramer (CAP-1)+ cells to that of total emigrated cells. bThe cytotoxicity was evaluated at the effector (DTH site-derived cultured cells) to target (SW480 cells) ratio of 50:1. The results were presented as mean percentage of cell lysis. The cytotoxicity against LoVo cells were used as control and presented as mean percentage of cell lysis in parentheses. cCD8+ T lymphocytes derived from DTH site-derived cultured cells were cocultured with CAP-1-pulsed T2 cells or Ssp-1-pulsed T2 cells (in parentheses) for 24 hours. IFN-γ in the coculture supernatant was measured by enzyme-linked immunosorbent assay were presented as mean level of IFN-γ. dThe DTH responses before the treatments (baseline) and 2 weeks after the treatments (post-treatments) against autologous Aex were evaluated. The results presented here were for diameter in millimeter of the response sites.